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ABSTRACT. Background: Tiredness is used in some characterizations of major 
depressive disorder (MDD). Transcranial magnetic stimulation (TMS) lowers all 
symptoms of MDD. Objective: To explore whether, 1) a visual analogue scale (VAS) 
for tiredness is a valid and reliable measure of a feature of MDD, and 2) TMS 
treatment reduces subjective tiredness occurring in MDD. Method: A naturalistic 
study of treatment with 10 Hz TMS. Completed pre- and post-treatment: HAMD-6, 
a visual analogue scale (VAS-6), the Clinical Global Impression – Severity (CGI-S) 
and a ‘VAS-tiredness’. Two groups received TMS. Acute course: N=52 participants 
suffering acute MDD, received 20 treatment courses (total courses 86). Relapse 
prevention (RP) course: N=26 participants suffering chronic relapsing MDD received 
scheduled episodic courses over 3 days; (total courses 266). VAS-tiredness scores 
were compared with the standardized tool results. Results: There were significant 
medium to large correlations between pre- and post-treatment VAS-tiredness and the 
standard depression measures (HAMD-6 .406 to .447, VAS-6 .446 to .525, CGI-S 
.348 to .407; all p<.001). TMS treatment produced a significant reduction in VAS-
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tiredness in both (Acute course and RP) groups (main effect: F(1,350)=147.3, 
p<.001, η2=.30). The two groups displayed difference in the pre-treatment VAS-
tiredness with the Acute group having higher scores pre-treatment. Post-treatment 
tiredness scores were similar. Conclusion: VAS-tiredness is a valid measure of a 
feature of MDD. VAS-tiredness provides potentially useful information and com- 
plements standard mood tools. TMS treatment can reduce tiredness in MDD. 
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Introduction 
 
Tiredness is defined by English dictionaries as, “The state of wishing to sleep 
or rest” and has various synonyms. In clinical research a distinction has been 
attempted between tiredness (‘natural tiredness’) and fatigue (‘unnatural 
tiredness’) (Grape et al., 2017), but has not been widely embraced. The term 
fatigue occurs in discussions of somatic disease such as multiple sclerosis and 
rheumatoid arthritis. A systematic review of studies of people presenting to 
general practice complaining of tiredness (Stadje et al., 2016) found serious 
somatic disease was rare and the most the common diagnosis was depression 
(18%). 
Silverstein (1999) described “somatic depression” – a variation more com- 
mon in females, characterized by fatigue and appetite and sleep disturbances. 
Vaccarino et al. (2008) report that ‘feeling fatigued, weak and tired all over’ 
is the most common somatic symptom of major depressive disorder (MDD), 
with 78% of patients reporting moderate or higher levels. Crowe et al. (2018) 
used the Experience Sampling Method to capture the within-day dynamics of 
various features of people with MDD and healthy controls. The MDD group 
experienced a significantly different pattern of tiredness – displaying a flatter 
course throughout the day. Chu et al. (2019) confirm tiredness and related 
sleep issues are possible symptoms of inflammation-related depression and 
are used as markers of response to anti-inflammatory medication. 
The persistence of isolated symptoms following the treatment of MDD 
has been described (Katon et al., 1999). Ghanean et al. (2018) report that 
after treatment for depression, 10–35% of patients continue to experience 
fatigue, and suggest possible pharmacological mitigation options. The impact 
of Transcranial Magnetic Stimulation (TMS) on subjective tiredness in MDD 
has received little attention. 
Tiredness does not appear as a heading in the 17 item Hamilton Depression 
Rating Scale (HAMD-17) (Hamilton, 1960) or the Positive and Negative 
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Affect Scale (Crawford and Henry, 2004). Lassitude is one of 10 diagnostic 
criteria of the Montgomery-Asberg Depression Rating Scale (Montgomery 
and Åsberg, 1979), low energy is one of 20 items listed in the Cornell 
Dysthymia Rating Scale (Cohen, 1997), and fatigue or loss of energy is one 
of 9 criteria of MDD in the 5th edition of the Diagnostic and Statistical 
Manual (Association, 2013). Tiredness was one of three primary symptoms 
of MDD in the 10th edition of International Classification of Diseases 
(Organization, 1992). It has less prominence in the ICD-11 but remains as 
part of the neurovegetative symptom cluster (Organization, 2018). Feeling 
tired or having little energy is one of 9 criteria in the subjective Patient Health 
Questionnaire depression module (Kroenke et al., 2001). Thus, tiredness and 
synonyms are measured by many but not all mood assessment tools. 
We have used the HAMD-6 in a series of studies of TMS in the treatment 
of MDD (Pridmore et al., 2018; May and Pridmore, 2019). HAMD-6 criterion 
2 ‘work and activities’ scores feelings of ‘fatigue or weakness’ as a low-
severity feature. Criterion 3 ‘somatic symptoms’ scores ‘loss of energy and 
fatigability’ as a mid-level severity feature. Criterion 6 ‘retardation’ is an 
observational assessment of motor activity – the relationship of observed 
retardation to subjective tiredness is unknown. Thus, in the HAMD-6, fatigue/ 
fatigability is dispersed rather than a single entity and the term tiredness is 
not used. 
The visual analogue scale has a long history in the quantification of 
subjective experience (Cowdry and Gardner, 1991). We developed a 6-item 
version (VAS-6) to complement the HAMD-6 – the traditional 10 cm line 
with anchor points at either end. The 6th item, the objective quantification of 
retardation, did not align with the VAS schema – thus, we developed anchor 
points concerning subjective experience of the ability to concentrate. In a 
large naturalistic study, we established the VAS-6 as a valid subjective 
measure of the core aspects of depression as measured by the objective 
HAMD-6 (May and Pridmore, 2019).  
We found no report focusing on the impact of TMS on subjective tiredness 
in MDD. Kakuda et al. (2016) studied TMS in the treatment of chronic 
fatigue syndrome and reported a reduction in fatigue, using a VAS which 
they developed for that purpose. Fitzgibbon et al. (2018) studied TMS in 
fibromyalgia and reported a reduction in fatigue using a Multidimensional 
Fatigue Inventory.  
The aim was to understand: 1) whether VAS-tiredness is a valid measure 
of a feature/s of MDD, 2) whether TMS treatment reduces the subjective 
tiredness (measured by VAS-tiredness) occurring in MDD, 3) the rate of 
change of tiredness for different types of TMS treatment. 
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Method 
 
Participants 
We provide TMS to inpatients at a private psychiatric hospital in an Aus- 
tralian capital city. This naturalistic study was approved by The Melbourne 
Clinic Research Ethics Committee. On admission patients give written ap- 
proval for their deidentified data to be analysed and published anonymously. 
We provide two TMS treatment programs: 1) an ‘Acute course’ for in- 
dividuals experiencing acute MDD – comprising 20 daily treatment sessions 
(with a 2 day rest after the 10th day), and 2) a ‘Relapse prevention’ (RP) 
course (Pridmore et al., 2018; Pridmore and May, 2018) – which is similar to 
what has been termed “maintenance” TMS (Fitzgerald et al., 2013) – this is 
provided to people with a history of frequent relapse – comprising 5 TMS 
sessions over 3 days, repeated according to clinical need – not more fre- 
quently than 4 weekly and usually at 5–6 week intervals. All participants 
must meet the diagnostic criteria for MDD according to DSM-5 criteria 
(Association, 2013). 
 
Measures 
Our standard assessment includes pre- and post-treatment HAMD-6, VAS-6 
and Clinical Global Impression for Severity (CGI-S) (Guy, 1976). The 6-item 
Hamilton Depression Rating Scale (HAMD-6) (O’Sullivan et al., 1997) is 
superior to the HAMD-17 in terms of transferability, scalability and respon- 
siveness (Hooper and Bakish, 2000; Timmerby et al., 2017) and is unidimen- 
sional (Kieslich da Silva et al., 2018). It has been successfully applied in 
MDD, bipolar depression and depression with mixed features. It is described 
as “reliable, valid and sensitive to change” and “a clinically useful measure” 
(Lee et al., 2017). The CGI-S is an assessment of the severity of symptoms 
of mental disorders, made by a trained clinician on the basis of clinical 
experience in psychiatry (Busner and Targum, 2007; Guy, 1976). Ratings are 
from 1 (Normal, not at all ill) through to 7 (Among the most extremely ill 
patients). It is reliable and widely used (Pinna et al., 2015). The VAS-6 
corresponds to the items from the HAMD-6 (May and Pridmore, 2019). For 
this study we also administered pre- and post-treatment a VAS – a 10 cm 
line with the anchor points: “Most tired possible” and “Not at all tired”, 
which was termed ‘VAS-tiredness’. 
 
Procedure 
In both the Acute and RP courses, TMS is provided to the left prefrontal 
cortex, at 110% motor threshold, 10 Hz stimulation, 4 second trains, 15 
second intertrain intervals, 70 trains per day. Participants completed the 
measures pre- and post-treatment. 
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Data Analysis 
Repeated measures ANOVA were used to compare pre- and post-treatment 
scores by group (Acute or RP) for the variables of interest. Mixed modelling 
using random effects was used to understand any influence of repeated 
courses and group on the change in VAS-tiredness. Pearson correlations were 
used to analyse associations between variables. Change scores were cal- 
culated as: pre score minus post score. All data were entered into SPSS 25 
for analysis. 
 
Results 
 
Participant characteristics 
135 Acute patients and 72 RP patients received treatment. There were 52 
participants with tiredness data in the Acute group and 26 in the RP group, 
totalling 78 participants hereon used in data analyses. Of the participants in 
the Acute group with tiredness data, the mean age was 41.5 years (SD=14.0) 
with 43 female (83%). In the RP group the mean age was 45.5 years 
(SD=15.0) with 23 female (88.5%). Of the Acute group, 12 patients received 
more than one course, for a total of 86 acute courses. Of the RP group, all 
received multiple courses for a total of 266 RP courses. 
 
Change in symptoms following treatment 
Table 1 shows the means and standard deviations of the pre- and post-
treatment scores for the VAS-tiredness, HAMD-6, VAS-6, and CGI-S. There 
was a significant decrease in tiredness scores following TMS treatment, main 
effect of time F(1,350)=147.3, p<.001, η2=.30, a significant difference in 
tiredness between the two groups, F (1,350)=10.4, p<.001, η2=.03 and a time 
by group interaction, F (1,350)=17.4, p<.001, η2=.05. This showed that the 
Acute group had a higher tiredness score than the RP group at the beginning 
of treatment, but they had similar tiredness levels following treatment, 
Figure 1. There were also significant decreases in HAMD-6 and VAS-6 total 
scores and for the CGI-S following TMS treatment. The same interaction 
effect was found for these three measures, with pre-treatment scores being 
higher in the Acute group but having similar levels to the RP group post-
treatment. Results of the mixed modelling showed there was no effect of the 
number of repeat treatments received on the change in VAS-tiredness score 
(p=.49). 
 
Associations between tiredness and other depression measures 
Associations between tiredness and other depression measures, both pre- and 
post-treatment, are shown in Table 2. As expected, in the whole sample VAS-
tiredness before and after treatment correlated with the corresponding HAMD-
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6, VAS-6 and CGI-S. Change in these scores were also correlated with 
change in VAS-tiredness in the whole sample. Considering the groups 
separately, the RP group showed the same significant associations as the 
whole sample, but the Acute group had fewer significant associations, par- 
ticularly at pre-assessment. 
 
Rate of change for Acute and RP treatment 
We were interested to investigate the effect of individual treatments and time 
on tiredness levels (as measured using VAS-tiredness). The Acute treatment 
takes 22 days and is comprised of 20 treatments (with a two day respite after 
10 days). The VAS-tiredness pretreatment score was 7.5 and the posttreat- 
ment score was 4.9, giving a difference of 2.6. This gives a reduction in 
tiredness units per treatment of 0.13, and per day of 0.12. The RP treatment 
is 5 treatment sessions over 3 days. VAS-tiredness scores pre- and post-
treatment were 6.0 and 4.7 – giving a difference of 1.3. This gives a 
reduction in tiredness units per treatment of 0.26 and per day of 0.5. 
 
Discussion 
 
The aims of this study were to explore whether VAS-tiredness was a valid 
measure of a feature/s of MDD and whether TMS treatment reduced the 
subjective tiredness (measured by VAS-tiredness) occurring in MDD. We 
found the VAS-tiredness measure showed consistent medium to large 
correlations with the other depression measures, notably the clinician rated 
HAMD-6 and corresponding self-report VAS-6, in the whole group. Change 
in tiredness was association with change in depression. We also found self-
reported tiredness decreased in participants treated with TMS. This indicates 
that tiredness as measured using the VAS-tiredness is a valid feature of 
depression and this symptom is reduced through TMS treatment. 
This study also aimed to explore the rate of change in tiredness for 
different treatment schedules. The change per treatment for the RP group 
was almost twice than that for the Acute group. This is consistent with the 
Acute group being much more severely depressed on admission (HAMD-6 
of 10.8, compared to the RP group, 6.9). For the RP group, the change per 
day is almost twice than the change per treatment. Thus, when the treatment 
is doubled, the improvement is almost doubled. This is consistent with the 
new concept of “accelerated treatment” – the administration of multiple 
treatment sessions per day (Rachid, 2019). 
The limitations of this study are that it was not blinded or placebo 
controlled, however, it is doubtful that introducing such conditions would 
have influenced the outcome. This was an observational study in which a 
large number of real patient experiences were collected and analysed with 
appropriate statistical methods. It may have been beneficial to record VAS-
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tiredness more frequently – but, this would have added to the patient 
experience of being an ‘experimental subject’. Instead, we examined VAS-
tiredness pre- and post-treatment along with the standard instruments we 
have applied in a routine manner for some years. 
Before treatment, the VAS-tiredness was higher for Acute course (7.5) 
than RP course patients (6.0). This was expected. Tiredness correlates with 
levels of depression. Acute course patients are suffering acute MDD which 
has not responded to (usually) long periods of psychotherapy and pharma- 
cological treatment, whereas the RP patients have recently (usually, about 4-
5 weeks ago) been in or very close to remission. Post-treatment VAS-
tiredness was very similar for Acute course (4.9) and RP course (4.7) 
patients. Again, this was expected. While the Acute course patients began 
with a higher VAS-tiredness, they received four times more treatment.  
Remission is operationalized as a HAMD-6 score of <4 (Bech et al., 
2007). Thus, both groups achieved remission and the VAS-tiredness scores 
could be expected to be similar. Bandelow et al. (2006) state that CGI-S 
score of 2 or less indicates remission. Pre-treatment, overall, Acute and RP 
groups are greater than moderately ill. After treatment overall and RP group 
are in remission, and at 2.1, the Acute group is very close to remission.  
It was also found that correlations between the VAS-tiredness and other 
measures were non-significant or low only for the Acute group pre-treatment 
for the HAMD-6 and CGI-S, but moderate to strong post-treatment in this 
group. In the RP group correlations were moderate to strong both pre- and 
post-treatment. This phenomenon has been found in our previous research 
comparing self-report on the VAS-6 and clinician report on the HAMD-6 
(May and Pridmore, 2019). This finding likely relates to two possibilities. 
New patients in the Acture group may not yet be familiar with their own 
depression symptoms, with their knowledge improving during treatment 
resulting in stronger clinician and self-report correlations post-treatment. The 
RP group in contrast are familiar with depression symptoms given their 
various prior treatments and episodes of depression. Alternatively, new 
patients may not be well known to staff and hence there may be a dis- 
crepancy in their initial clinical ratings which reduces over time as they 
remain in hospital for their Acute treatment and become better known to 
staff. 
This study would have been problematic if TMS caused tiredness. We 
found one mention of “excessive tiredness” as a side-effect in one large 
review (Rossi, 2009) – but we could not locate the report of this side effect 
within the indicated journal. Tiredness is not mentioned as a side-effect in 
authoritative textbooks (Pascual-Leone et al., 2002; George and Belmaker, 
2007). A recent review of “accelerated” TMS (Rachid, 2019) (in which 
many treatment sessions are provided in one day) also makes no mention of 
tiredness as a side-effect. Authors reporting the impact of TMS on the 
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symptoms of chronic fatigue syndrome (Kakuda et al., 2016) and fibro- 
myalgia (Fitzgibbon et al., 2018) identified reductions in fatigue, rather than 
increases. Thus, we found no convincing evidence indicating TMS causing 
tiredness. 
Nevertheless, during this study, occasional patients have reported, in 
unstructured clinical conversations, that treatment was associated with mid-
course increased tiredness. This tiredness was not cumulative and prominent 
tiredness is not apparent in the latter stages of courses of 20 treatments. We 
conceptualized this occasional mid-course tiredness as a feature of the 
recovery process. It is possible that should the pre-treatment mental state 
feature high arousal (or a constellation of other symptoms) producing an in- 
ability to relax, when the mental state improves (with treatment) the patient 
may be more able to experience tiredness (and restorative sleep). We are also 
considering whether some acutely depressed individuals lack the necessary 
drive for activity, but as drive improves (with treatment) they perhaps ‘make 
up for lost time’, do more, and experience more natural tiredness/sleep. 
In this study we rated tiredness at intake and discharge, but not during the 
course of treatment. To explore the observation of occasional mid-course 
tiredness we are planning a future study incorporating daily rating of VAS-
tiredness and other complementary tools. We are also planning to explore 
the impact (if any) of TMS on irritability, which has recently been described 
as an overlooked feature of MDD (Jha et al., 2019). 
In conclusion, VAS-tiredness is a subjective measurement which is addi- 
tional to the items of the VAS-6, which is based on and is complementary to 
the objective HAMD-6. VAS-tiredness ratings correlate with the total HAMD-
6 and VAS-6 ratings and are a potentially useful addition in the study of 
patients experiencing MDD. 
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Figure 1 Change in tiredness scores for the Acute and Relapse Prevention (RP) 
                groups pre and post treatment, with 95% Confidence Intervals.  
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Table 1 Pre post means and standard deviations for the variables of interest 
Measure Pre Post 
Whole group   
     Tiredness-VAS (N=352) 6.3 (2.4) 4.8 (2.4) 
     HAMD-6 total (N=351) 7.8 (3.3) 3.4 (2.3) 
     VAS-6 (N=351) 27.1 (12.5) 16.7 (9.7) 
      CGI-S (N=350) 3.4 (1.1) 1.8 (0.8) 
Acute group   
     Tiredness-VAS (N=86) 7.5 (1.9) 4.9 (2.4) 
     HAMD-6 total (N=86) 10.8 (2.0) 4.0 (2.8) 
     VAS-6 (N=86) 38.4 (8.8) 20.0 (10.4) 
      CGI-S (N=84) 4.3 (0.7) 2.1 (1.0) 
Relapse Prevention group   
     Tiredness-VAS (N=266) 6.0 (2.5) 4.7 (2.5) 
     HAMD-6 total (N=265) 6.9 (3.0) 3.2 (2.1) 
     VAS-6 (N=265) 23.4 (11.3) 15.7 (9.3) 
      CGI-S (N=266) 3.1 (1.0) 1.8 (0.8) 
 
Table 2 Pearson correlations between VAS-tiredness  
              and HAMD-6, VAS-6 and CGI-I 
 Whole group Acute RP 
Pre VAS-Tiredness    
     Pre HAMD-6 Total (N=351, 86, 265) .447** .158 .415** 
     Pre VAS-6 Total (N=352, 86, 266) .525** .284** .508** 
     Pre CGI-I (N=352, 86, 266) .407** .056 .381** 
Post VAS-Tiredness    
     Post HAMD-6 Total (N=352, 86, 266) .406** .463** .390** 
     Post VAS-6 Total (N=351, 86, 265) .446** .457** .448** 
     Post CGI-I (N=350, 84, 266) .348** .396** .335** 
Change in VAS-Tiredness (T2-T1)    
     Change HAMD-6 Total (N=352, 86,265) .372** .213* .362** 
     Change VAS-6 Total (N=351, 86, 265) .421** .354** .384** 
     Change CGI-I (N=350, 84, 266) .307** .130 .314** 
**p<.01, *p<.05 
 
 
 
 
 
 
 
 
 
